LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LXRX
Lexicon Pharmaceuticals, Inc.
There isn't enough reported data to score LXRX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LXRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
LXRX's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LXRX PE Valuation
LXRX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LXRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect LXRX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LXRX on earnings quality, reporting a profit while its opponent remains loss making.
LXRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.14 | +$0.04 |
| Q2 2026 | -$0.15 | +$0.17 |
| Q1 2026 | -$0.07 | +$0.43 |
| Q4 2025 | -$0.14 | +$0.49 |
| Q3 2025 | -$0.18 | +$0.57 |
| Q2 2025 | -$0.32 | +$0.46 |
| Q1 2025 | -$0.50 | +$0.33 |
| Q4 2024 | -$0.63 | +$0.17 |
LXRX is still losing money, but far less than before: $0.14 per share over the past year, against $1.05 at its worst in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LXRX on profitability, with a higher operating margin.
LXRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | -21% |
| Q2 2026 | $692K | -98% |
| Q1 2026 | $21.1M | +1572% |
| Q4 2025 | $5.5M | -79% |
| Q3 2025 | $14.2M | +710% |
| Q2 2025 | $28.9M | +1653% |
| Q1 2025 | $1.3M | +12% |
| Q4 2024 | $26.6M | +3683% |
LXRX's revenue has slid since its 2025 peak: $11M last quarter, down 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -129% | -43 points |
| Q2 2026 | -3835% | -3848 points |
| Q1 2026 | -4.7% | +2030 points |
| Q4 2025 | -269% | -146 points |
| Q3 2025 | -86% | +3554 points |
| Q2 2025 | 13% | +3374 points |
| Q1 2025 | -2035% | +1977 points |
| Q4 2024 | -123% | +6534 points |
LXRX's operating margin was −129% last quarter, down 43 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LXRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
LXRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.1M | +$15.8M |
| Q1 2026 | -$14.7M | +$29M |
| Q4 2025 | -$17.2M | +$4.7M |
| Q3 2025 | -$23.8M | +$30.1M |
| Q1 2025 | -$43.8M | +$11.4M |
| Q4 2024 | -$22M | +$28.6M |
| Q3 2024 | -$53.9M | -$12.2M |
| Q2 2024 | -$48.8M | -$10.5M |
LXRX has burned cash in almost every quarter: −$49M over the past year, against −$144M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LXRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LXRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +7.3M shares |
| 1 year | +22% | +81.6M shares |
| 3 years | +82% | +200M shares |
| 5 years | +205% | +299M shares |
| Available history | +319% | +339M shares |
LXRX has 445M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $1.7M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $824,000 |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LXRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | -1.8x | Net Cash |
| Q1 2020 | 1.9x | Healthy |
| Q4 2019 | 1.4x | Healthy |
LXRX has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LXRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 27.1 | Neutral |
LXRX's weekly RSI is 48 (neutral) and its Stochastic is 27 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LXRX PE vs Healthcare Sector
| Metric | LXRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LXRX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LXRX on trend strength, trading above more of its moving averages.
LXRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.66 | 9.6% above |
| 20 week MA | $2.02 | 9.9% below |
| 50 week MA | $1.79 | 1.7% above |
| 100 week MA | $1.36 | 34% above |
| 200 week MA | $1.61 | 13% above |
LXRX's trend is mixed: it's above four of its five weekly moving averages, and 13% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
LXRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.26 | $3.49 | -18% |
| 2021 | $3.49 | $4.36 | +25% |
| 2022 | $4.36 | $1.95 | -55% |
| 2023 | $1.95 | $1.53 | -22% |
| 2024 | $1.53 | $0.77 | -50% |
| 2025 | $0.77 | $1.23 | +60% |
| 2026 YTD | $1.23 | $1.82 | +48% |
LXRX has the edge over LLY on returns for 2026, with the stronger performance.